Seminars in Cancer Biology

Article	Citations
Editorial Board	412
Editorial Board	364
Dissecting the heritable risk of breast cancer: From statistical methods to susceptibility genes	286
Small secretory proteins of immune cells can modulate gynecological cancers	257
Advances in biology and novel treatments of SCLC	232
Breast cancer metastasis to bone: From epithelial to mesenchymal transition to breast osteoblast-like cells	224
Targeting Hippo signaling pathway by phytochemicals in cancer therapy	204
Emerging applications of bacteria as antitumor agents	197
Unveiling the role of PIK3R1 in cancer: A comprehensive review of regulatory signaling and therapeutic implications	195
Deregulated transcription factors in the emerging cancer hallmarks	190
The molecular chaperone TRAP1 in cancer: From the basics of biology to pharmacological targeting	185
Critical DNA damaging pathways in tumorigenesis	183
Carbonic anhydrase IX: A tumor acidification switch in heterogeneity and chemokine regulation	182
Biology of cancer; from cellular and molecular mechanisms to developmental processes and adaptation	180
Updated review on green tea polyphenol epigallocatechin-3-gallate as a cancer epigenetic regulator	177
Multifaceted role of chemokines in solid tumors: From biology to therapy	169
Editorial Board	168
Special issue: Deregulated transcription factors in the cancer therapeutic challenges: An update on cancer stemness features	165
Editorial Board	161
Gut microbes in gastrointestinal cancers	156
Extracellular vesicles associated microRNAs: Their biology and clinical significance as biomarkers in gastrointestinal cancers	156
Association of Chlamydia and Mycoplasma infections with susceptibility to ovarian cancer: A systematic review and meta-analysis	155
Erratum to “RNA regulatory mechanisms controlling TGF-β signaling and EMT in cancer” [Semin. Cancer Biol. 102–103 (2024) 4–16]	150
Genomic profiling of sporadic liver metastatic colorectal cancer	148
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy	141

Multifaceted functions of chronic inflammation in regulating tumor dormancy and relapse	139
Excess body weight and postmenopausal breast cancer: Emerging molecular mechanisms and perspectives	139
PIWI-interacting RNAs in human cancer	134
Innovative trial design in precision oncology	133
Thinking small to win big? A critical review on the potential application of extracellular vesicles for biomarker discovery and new therapeutic approaches in pancreatic cancer	130
Molecular targets of tyrosine kinase inhibitors in thyroid cancer	126
Microbiome dysbiosis and epigenetic modulations in lung cancer: From pathogenesis to therapy	120
Targeting monocarboxylate transporters (MCTs) in cancer: How close are we to the clinics?	119
Origins and molecular effects of hypoxia in cancer	117
The IL-1 family in tumorigenesis and antitumor immunity	117
Immune cellular components and signaling pathways in the tumor microenvironment	116
Anticancer properties of chimeric HDAC and kinase inhibitors	116
Genome chaos: Creating new genomic information essential for cancer macroevolution	114
Enhancing head and neck tumor management with artificial intelligence: Integration and perspectives	111
New biological and immunological approaches to cancer therapy: Basic and clinical aspects	111
Targeting the “undruggable”: RNA-binding proteins in the spotlight in cancer therapy	110
Reprogramming of glycolysis by chemical carcinogens during tumor development	108
Modulation of the tumor microenvironment by natural agents: implications for cancer prevention and therapy	108
Cellular stress responses and metabolic reprogramming in cancer progression and dormancy	104
Extracellular vesicles in glioblastoma: Biomarkers and therapeutic tools	104
Multi-omic markers of intraductal papillary mucinous neoplasms progression into pancreatic cancer	103
Therapy-induced modulation of extracellular vesicles in hepatocellular carcinoma	103
Anticancer natural products targeting immune checkpoint protein network	101
Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model systems	100
Editorial Board	100
Metabolic landscape and rewiring in normal hematopoiesis, leukemia and aging	99
Atrial fibrillation in cancer patients: Epidemiology, identification and management	98
Regulation of the aryl hydrocarbon receptor in cancer and cancer stem cells of gynecological malignancies: An update on signaling pathways	97
Insight into the role of multiple signaling pathways in regulating cancer stem cells of gynecologic cancers	97
Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics	96
Advancement of cancer immunotherapy using nanoparticles-based nanomedicine	96
The intricacies of NRF2 regulation in cancer	96
How far have we explored fungi to fight cancer?	95
Integrative microphysiological tissue systems of cancer metastasis to the liver	95
Curcumin and colorectal cancer: An update and current perspective on this natural medicine	95
Vibrational spectroscopy for decoding cancer microbiota interactions: Current evidence and future perspective	94
Role of LDH in tumor glycolysis: Regulation of LDHA by small molecules for cancer therapeutics	94
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer	94
Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors	90
Editorial Board	89
Editorial Board	88
The role of RNA processing and regulation in metastatic dormancy	88
Prostate cancer liver metastasis: Dormancy and resistance to therapy	88
Cytotoxic activity of l-lysine alpha-oxidase against leukemia cells	88
Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications	87
Drivers of centrosome abnormalities: Senescence progression and tumor immune escape	87
Emerging perspectives on growth factor metabolic relationships in the ovarian cancer ascites environment	86
Transcription networks rewire gene repertoire to coordinate cellular reprograming in prostate cancer	85
Role of ubiquitination-driven metabolisms in oncogenesis and cancer therapy	84
The foundational framework of tumors: Gametogenesis, p53, and cancer	84

MITOCHONDRIAL CHOLESTEROL AND CANCER	83
Emerging roles of long noncoding RNAs in chemoresistance of pancreatic cancer	82
The role of tumor microenvironment and exosomes in dormancy and relapse	80
Clinical utility of whole-genome sequencing in precision oncology	80
Microbiota and lung cancer	78
Chaperonins in cancer: Expression, function, and migration in extracellular vesicles	77
Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling	76
Advancements in small cell lung cancer	75
Functionalized-DNA nanostructures as potential targeted drug delivery systems for cancer therapy	73
Plant lectins and their usage in preparing targeted nanovaccines for cancer immunotherapy	72
BubR1 and SIRT2: Insights into aneuploidy, aging, and cancer	72
Benefits and limitations of nanomedicine treatment of brain cancers and age-dependent neurodegenerative disorders	72
Epithelial-mesenchymal transition: Insights into nickel-induced lung diseases	72
Recent trends and advances in the epidemiology, synergism, and delivery system of lycopene as an anti-cancer agent	71
Analytical demands to use whole-genome sequencing in precision oncology	71
Pattern recognition of tumor dormancy and relapse beyond cell-intrinsic and cell-extrinsic pathways	70
Oncolytic viruses as a promising therapeutic strategy against the detrimental health impacts of air pollution: The case of glioblastoma multiforme	69
Holistic immunomodulation for small cell lung cancer	69
Sanitation enzymes: Exquisite surveillance of the noncanonical nucleotide pool to safeguard the genetic blueprint	67
Targeting tumor cell senescence and polyploidy as potential therapeutic strategies	66
CRISPR/Cas mediated epigenome editing for cancer therapy	65
Targeting p53 for the treatment of cancer	64
Biomarkers, omics and artificial intelligence for early detection of pancreatic cancer	64
Arsenic co-carcinogenesis: Inhibition of DNA repair and interaction with zinc finger proteins	64
Urinary microbiota and bladder cancer: A systematic review and a focus on uropathogens	64
Chemopreventive effects of anthocyanins on colorectal and breast cancer: A review	64
Targeting OXPHOS and the electron transport chain in cancer; Molecular and therapeutic implications	63
Molecular mechanisms of pulmonary carcinogenesis by polycyclic aromatic hydrocarbons (PAHs): Implications for human lung cancer	63
Novel molecular regulators of breast cancer stem cell plasticity and heterogeneity	63
Artificial intelligence for breast cancer detection in mammography and digital breast tomosynthesis: State of the art	62
Excess body weight: Novel insights into its roles in obesity comorbidities	61
Anticancer activity of lactic acid bacteria	61
Special Issue: Epigenetic regulation of cancer progression: Promises and progress	61
Paradoxes of cancer: Survival at the brink	61
Microbes in gynecologic cancers: Causes or consequences and therapeutic potential	61
Thematic issue ‘tumor glycolysis’	61
Cytokines chattering in pancreatic ductal adenocarcinoma tumor microenvironment	61
Editorial Board	60
Editorial Board	59
SR-BI as a target of natural products and its significance in cancer	58
Human cell polyploidization: The good and the evil	58
Characterizing and exploiting the many roles of aberrant H2B monoubiquitination in cancer pathogenesis	58
Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges	58
Beyond cell cycle regulation: The pleiotropic function of CDK4 in cancer	58
Deregulated transcription factors and poor clinical outcomes in cancer patients	58
Non-coding genome in small cell lung cancer between theoretical view and clinical applications	58
Tumor microenvironment conditions that favor vessel co-option in colorectal cancer liver metastases: A theoretical model	57
Accelerating antibody discovery and design with artificial intelligence: Recent advances and prospects	57
The crucial role of epigenetic regulation in breast cancer anti-estrogen resistance: Current findings and future perspectives	56
Exosome-based nanomedicine for cancer treatment by targeting inflammatory pathways: Current status and future perspectives	56
Gut microbiota and immunosenescence in cancer	55
The central role of mitochondria in the relationship between dietary lipids and cancer progression	55
Editorial Board	55
The impact of VEGF on cancer metastasis and systemic disease	55
TGF-β, EMT, and resistance to anti-cancer treatment	55
Transfer RNA-derived small RNA: A rising star in oncology	55
Possible connection between diet and microRNA in cancer scenario	54
The intricate nature of senescence in development and cell plasticity	54
Inflammation-targeted nanomedicine against brain cancer: From design strategies to future developments	54
cGAS/STING signalling pathway in senescence and oncogenesis	54
Role of endolysosome function in iron metabolism and brain carcinogenesis	54
Emerging role of pancreatic stellate cell-derived extracellular vesicles in pancreatic cancer	54
Putting the brakes on tumorigenesis with snake venom toxins: New molecular insights for cancer drug discovery	54
Extracellular vesicles as source for the identification of minimally invasive molecular signatures in glioblastoma	54
The role of RNA-binding proteins in the processing of mRNAs produced by carcinogenic papillomaviruses	54
Transcriptional factors targeting in cancer stem cells for tumor modulation	53
Precision diagnostics in lymphomas – Recent developments and future directions	53
Insights into the role of gut and intratumor microbiota in pancreatic ductal adenocarcinoma as new key players in preventive, diagnostic and therapeutic perspective	53
Microbes in lung cancer initiation, treatment, and outcome: Boon or bane?	53
Mechanisms and strategies of immunosenescence effects on non-small cell lung cancer (NSCLC) treatment: A comprehensive analysis and future directions	53
Epigenetic modifications of c-MYC: Role in cancer cell reprogramming, progression and chemoresistance	52
Remodeling of tumor microenvironment by cellular senescence and immunosenescence in cervical cancer	52
Alternative splicing in EMT and TGF-β signaling during cancer progression	52
Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities	51
Artificial intelligence aids in development of nanomedicines for cancer management	51
Exosomes and extracellular vesicles: Rethinking the essential values in cancer biology	51
Contributions of the distinct biophysical phenotype of polyploidal giant cancer cells to cancer progression	51
Obesity and main urologic cancers: Current systematic evidence, novel biological mechanisms, perspectives and challenges	51
Editorial Board	50
Predicting liver metastases growth patterns: Current status and future possibilities	50

Corrigendum to “How far have we explored fungi to fight cancer?” [86/Part 2 (2022) 976–989]	50
Editorial Board	50
Can medical imaging identify the histopathological growth patterns of liver metastases?	50
“Time” for obesity-related cancer: The role of the circadian rhythm in cancer pathogenesis and treatment	50
Editorial Board	50
Minimal residual disease in advanced or metastatic solid cancers: The G0-G1 state and immunotherapy are key to unwinding cancer complexity	50
Small cell lung cancer: Novel treatments beyond immunotherapy	50
Epigenetic deregulation in cancer: Enzyme players and non-coding RNAs	49
The altered lipidome of hepatocellular carcinoma	49
New insights into KLFs and SOXs in cancer pathogenesis, stemness, and therapy	49
Targeting oncogenic transcription factors in skin malignancies: An update on cancer stemness and therapeutic outcomes	49
Predictive biomarkers for response to immune checkpoint inhibition	49
Pro-tumoral functions of tumor-associated macrophage EV-miRNA	48
The role of surgery in platinum-resistant ovarian cancer: A call to the scientific community	48
Dysregulated FOXM1 signaling in the regulation of cancer stem cells	48
Nanoparticle-based drug delivery systems in cancer: A focus on inflammatory pathways	48
Regulation of cancer cell signaling pathways as key events for therapeutic relevance of edible and medicinal mushrooms	47
Exploiting transcription factors to target EMT and cancer stem cells for tumor modulation and therapy	47
Interplay of ferroptosis, cuproptosis, and PANoptosis in cancer treatment-induced cardiotoxicity: Mechanisms and therapeutic implications	47
Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs)	47
A role for partial epithelial-to-mesenchymal transition in enabling stemness in homeostasis and cancer	46
Nanoparticles: Attractive tools to treat colorectal cancer	46
The role of exercise in obesity-related cancers: Current evidence and biological mechanisms	45
Sphingolipids in embryonic development, cell cycle regulation, and stemness – Implications for polyploidy in tumors	45
Precision medicine in pediatric solid cancers	45
Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy	45
Hedgehog signaling mechanism and role in cancer	45
Inflammation targeted nanomedicines: Patents and applications in cancer therapy	45
Microbial polysaccharides: An emerging family of natural biomaterials for cancer therapy and diagnostics	44
Ethical challenges of precision cancer medicine	44
Current and emerging molecular and epigenetic disease entities in acute myeloid leukemia and a critical assessment of their therapeutic modalities	44
Liver prometastatic reaction: Stimulating factors and responsive cancer phenotypes	44
Understanding RNA-binding proteins	43
Recent advances of nanodrug delivery system in the treatment of hematologic malignancies	43
Dynamical hallmarks of cancer: Phenotypic switching in melanoma and epithelial-mesenchymal plasticity	43
Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond	42
Nutrient sensing of mTORC1 signaling in cancer and aging	42
The life cycle of polyploid giant cancer cells and dormancy in cancer: Opportunities for novel therapeutic interventions	42
Polyploid giant cancer cell characterization: New frontiers in predicting response to chemotherapy in breast cancer	42
Molecular pathogenesis, targeted therapies, and future perspectives for gastric cancer	42
Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease	42
Radiotherapy-induced remodeling of the tumor microenvironment by stromal cells	41
Preface for “Extracellular vesicles in cancer, from signalling mechanisms to therapeutic potential”	41
RB functions as a key regulator of senescence and tumor suppression	41
Lactate Dehydrogenase and its clinical significance in pancreatic and thoracic cancers	41
Epigenetic Regulation of Cancer Immune Cells	41
Inflammasomes in cancer: Effect of epigenetic and autophagic modulations	41
The two sides of Hippo pathway in cancer	41
A systems and computational biology perspective on advancing CAR therapy	41
Nanomedicines targeting the inflammasome as a promising therapeutic approach for cell senescence	40
Targeting cancer stem cells by nutraceuticals for cancer therapy	40
Harnessing computational spatial omics to explore the spatial biology intricacies	40
New approaches for targeting platinum-resistant ovarian cancer	40
Targeting stemness of cancer stem cells to fight colorectal cancers	40
p53/MDM2 signaling pathway in aging, senescence and tumorigenesis	39
Vaginal microbiome and cervical cancer	39
Towards artificial intelligence to multi-omics characterization of tumor heterogeneity in esophageal cancer	39
Immune functions as a ligand or a receptor, cancer prognosis potential, clinical implication of VISTA in cancer immunotherapy	39
Obesity and renal cell carcinoma: Biological mechanisms and perspectives	39
An update on vitamin D signaling and cancer	39
Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: Perspectives for immunotherapy of SCLC	39
Chemokine clouding and liver cancer heterogeneity: Does it impact clinical outcomes?	38
Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems	38
Extracellular Vesicle (EV) biohybrid systems for cancer therapy: Recent advances and future perspectives	38
New approaches in extracellular vesicle engineering for improving the efficacy of anti-cancer therapies	38
Thorny ground, rocky soil: Tissue-specific mechanisms of tumor dormancy and relapse	38
Special issue on “Excess body weight and cancer: Novel biologic insights and challenges”	38
Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin	38
Immunosenescence in skeletal muscle: The role-play in cancer cachexia chessboard	38
The depths of PD-1 function within the tumor microenvironment beyond CD8+ T cells	38
Integrated approaches for precision oncology in colorectal cancer: The more you know, the better	38
Connecting the dots in the associations between diet, obesity, cancer, and microRNAs	38
Chemokines in triple-negative breast cancer heterogeneity: New challenges for clinical implications	37
Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments	37
Corrigendum to “Mitochondrial mutations and mitoepigenetics: Focus on regulation of oxidative stress-induced responses in breast cancers” [Semin. Cancer Biol. 83 (2022) 556–569]	37
Editorial Board	37
Status quo of Extracellular Vesicle isolation and detection methods for clinical utility	37
MicroRNA and ER stress in cancer	37
Editorial Board	37
Editorial Board	37
The cell cycle revisited: DNA replication past S phase preserves genome integrity	37
Extracellular vesicles for precision medicine in prostate cancer – Is it ready for clinical translation?	37
Special issue: Diet, lipids, and cancer: From Pathogenic mechanisms to potential therapeutic strategies	37
Editorial: Regulating cell cycle-related activities: The right target for cancer therapy	37
Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany	36
Clonal hematopoiesis, cardiovascular disease and cancer treatment-induced cardiotoxicity	36
High-Throughput immunogenetics for precision medicine in cancer	36
Polyploidy in development and tumor models in Drosophila	36
LDL, HDL and endocrine-related cancer: From pathogenic mechanisms to therapies	36
Epigenetic regulation of CXCR4 signaling in cancer pathogenesis and progression	36
Special issue: Modulation of immune checkpoint proteins and their networks in cancer progression	36
Melanoma in the liver: Oxidative stress and the mechanisms of metastatic cell survival	36
Uveal melanoma pathobiology: Metastasis to the liver	36
Counter regulation of tumor angiogenesis by vascular endothelial growth factor and thrombospondin-1	36
Cancer cell populations	36